WBC (leukocytes) - ANSWER 3.2-11.3
RBC (erythrocytes) - ANSWER M: >4.2
F: >3.5
Hemoglobin - ANSWER Male: 14-18
Female: 12-16
Hematocrit - ANSWER M: >39%
F: >33%
MCV (mean corpuscular volume) - ANSWER 76-100
Carvedilol P450 Substrate - ANSWER 2D6
Metoprolol P450 Substrate - ANSWER 2D6
Codeine P450 Substrate - ANSWER 2D6
PPIs P450 Substrate - ANSWER 2C19
Clopidogrel P450 Substrate - ANSWER 2C19
Citalopram P450 Substrate - ANSWER 2C19
Benzos (alp/dia/mida/triaz) P450 Substrate - ANSWER 3A4
2D6 inhibitors - ANSWER +++ bupropion, fluoxetine, paroxetine
++ duloxetine
2C19 inhibitors - ANSWER PPIs
, fluoxetine/fluvoxamine
2D6 inducers - ANSWER none - 2D6 considered non-inducible enzyme
Antipsychotic P450 substrate - ANSWER mostly 2D6
metformin causes what deficiency - ANSWER B12
SGLT2 inhibitor pearls (flozins) - ANSWER renally dosed, cardiac benefits
(empaglifloz)
DPP4 inhibitor pearls (gliptans) - ANSWER inc CHF hospitalization,
pancreatitis, renal limits, joint pain
GLP1 agonists pearls (natides) - ANSWER injectable, cardiac outcomes, more
effective than DPP4s
MMSE - ANSWER 24-30 normal
18-23 mild
10-17 mod
<10 sev
MoCA - ANSWER more effective than MMSE, 20+ languages
26-30 normal
<26 MCI or dementia
SBT and ADAS-Cog - ANSWER cognitive assessments
GDS - ANSWER Geriatric Depression Scale
PHQ - ANSWER PHQ2 or PHQ9, depression questionnarie
Cornell Scale - ANSWER for depression in Dementia
Hamilton - ANSWER depression scale, need training to perform
TMT - ANSWER trail making test - cognitive function
RBC (erythrocytes) - ANSWER M: >4.2
F: >3.5
Hemoglobin - ANSWER Male: 14-18
Female: 12-16
Hematocrit - ANSWER M: >39%
F: >33%
MCV (mean corpuscular volume) - ANSWER 76-100
Carvedilol P450 Substrate - ANSWER 2D6
Metoprolol P450 Substrate - ANSWER 2D6
Codeine P450 Substrate - ANSWER 2D6
PPIs P450 Substrate - ANSWER 2C19
Clopidogrel P450 Substrate - ANSWER 2C19
Citalopram P450 Substrate - ANSWER 2C19
Benzos (alp/dia/mida/triaz) P450 Substrate - ANSWER 3A4
2D6 inhibitors - ANSWER +++ bupropion, fluoxetine, paroxetine
++ duloxetine
2C19 inhibitors - ANSWER PPIs
, fluoxetine/fluvoxamine
2D6 inducers - ANSWER none - 2D6 considered non-inducible enzyme
Antipsychotic P450 substrate - ANSWER mostly 2D6
metformin causes what deficiency - ANSWER B12
SGLT2 inhibitor pearls (flozins) - ANSWER renally dosed, cardiac benefits
(empaglifloz)
DPP4 inhibitor pearls (gliptans) - ANSWER inc CHF hospitalization,
pancreatitis, renal limits, joint pain
GLP1 agonists pearls (natides) - ANSWER injectable, cardiac outcomes, more
effective than DPP4s
MMSE - ANSWER 24-30 normal
18-23 mild
10-17 mod
<10 sev
MoCA - ANSWER more effective than MMSE, 20+ languages
26-30 normal
<26 MCI or dementia
SBT and ADAS-Cog - ANSWER cognitive assessments
GDS - ANSWER Geriatric Depression Scale
PHQ - ANSWER PHQ2 or PHQ9, depression questionnarie
Cornell Scale - ANSWER for depression in Dementia
Hamilton - ANSWER depression scale, need training to perform
TMT - ANSWER trail making test - cognitive function
